<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214927</url>
  </required_header>
  <id_info>
    <org_study_id>1234.12</org_study_id>
    <nct_id>NCT02214927</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers</brief_title>
  <official_title>Relative Bioavailability of 10 mg BI 11634 Immediate Release Tablet (IR) Compared to 10 mg of Oral Solution Following Oral Administration in Healthy Male Volunteers (Open-label, Single-dose, Intra-individual Comparison); Determination of Pharmacokinetics of 5 mg, 10 mg and 25 mg IR-tablet Formulation (Open-label, Single Dose)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      -  Characterisation of the relative bioavailability of the IR-tablet vs. oral drinking
           solution (no primary endpoint in a statistical sense)

        -  Safety and tolerability of the IR-tablet formulation and solution

        -  PK profile of the single ascending doses of the IR-tablet formulation (including
           analysis of dose proportionality)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 10 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>up to 10 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in ECG</measure>
    <time_frame>up to 10 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 10 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 10 days after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in plasma after extravascular administration)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT) ratios between groups</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum aPTT prolongation</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% inhibition of endogenous Factor Xa</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>by Russel's Viper Venom test (RVV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum international normalized ratio (INR)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>compared between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent inhibition of thrombin generation by BI 11634</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent peak inhibition of thrombin generation</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum inhibition of thrombin generation BI 11634</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent prolongation of lag time</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the inhibition of the endogenous thrombin generation-time curve</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum prolongation of blood coagulation time</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
    <description>by HepTest® (Haemachem Inc.) and COAMATIC® Heparin test (Chromogenix)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 11634 single rising dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 11634 cross-over</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence: 1. tablet 2. drinking solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 11634 tablet</intervention_name>
    <arm_group_label>BI 11634 single rising dose</arm_group_label>
    <arm_group_label>BI 11634 cross-over</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 11634 drinking solution</intervention_name>
    <arm_group_label>BI 11634 cross-over</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian males according to the following criteria, based upon a complete
             medical history, including the physical examination, vital signs (blood pressure,
             pulse rate), 12-lead ECG, clinical laboratory tests

          -  Age ≥18 and ≤50 years

          -  Haemoglobin within the normal ranges

          -  Body Mass Index (BMI) ≥18.5 and BMI ≤29.9 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with Good clinical practice (GCP) and the local legislation

        Exclusion Criteria:

          -  Relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Relevant surgery of gastrointestinal tract

          -  History of any bleeding disorder or acute and chronic blood coagulation defect, for
             the subject itself or any person of his family as far as known

          -  History of gastric ulcera and cholecystectomy

          -  Occult blood in faeces

          -  Relevant diseases of the central nervous system (such as epilepsy) or psychiatric
             disorders or neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Relevant chronic or acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt;24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

          -  Use of acetylsalicylic acid or any other non-steroidal anti-inflammatory drugs (NSAID)
             within 2 weeks of study start until the end of study

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Alcohol abuse (more than 40 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Vulnerable subjects (e.g. persons kept in detention)

          -  Inability to understand and comply with protocol requirements, instructions and
             protocol-stated restrictions, the nature, scope and possible consequences of the study

          -  Subjects (including those who have had a vasectomy) who do not agree to use two
             methods of contraception, including barrier contraception (latex condoms with
             spermicide plus intrauterine device) when engaging in sexual activity with women of
             child bearing potential during the study and for 60 days after completion of the study

          -  Subjects with a history within the past six weeks of closed-head or torso trauma or
             deceleration injury such as an automobile accident or fall from a significant height
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

